Mateus Trinconi Cunha

Dr. Mateus Trinconi Cunha

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MCMateus Trinconi Cunha
Mateus Trinconi Cunha
MGMariana Carvalho Gouveia
Mariana Carvalho Gouveia
FNFelippe Lazar Neto
Felippe Lazar Neto
LTLaura Testa
Laura Testa
PHPaulo Marcelo Hoff
Paulo Marcelo Hoff
RBRenata Colombo Bonadio
Renata Colombo Bonadio

6 December 2022 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
SSSaulo Brito Silva
Saulo Brito Silva
CWCarlos Wagner S. Wanderley
Carlos Wagner S. Wanderley
JMJosé Flavio Gomes Marin
José Flavio Gomes Marin
MMMariana Petaccia de Macedo
Mariana Petaccia de Macedo
ENEllen Caroline Toledo Do Nascimento
Ellen Caroline Toledo Do Nascimento
GJGilberto de Castro Junior
Gilberto de Castro Junior
Background: A significant proportion of patients with non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with increased glycolysis is a hallmark of cancer and is involved in immune evasion, we used 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) to evaluate the baseline glycolytic parameters of patients with advanced NSCLC submitted to ICIs, and assessed their predictive value. Methods: 18F-FDG PET/CT results in the 3 months before ICIs treatment were included. Maximum standardized uptake values, whole metabolic tumor volume (wMTV), and whole-body total lesion glycolysis (wTLG) were evaluated. Cutoff values for high or low glycolytic categories were determined using receiver-operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were evaluated. Patients with a complete response and a matching group with resistance to ICIs underwent immunohistochemistry analysis. An unsupervised k-means clustering model integrating programmed cell death ligand 1 (PD-L1) expression, glycolytic parameters, and ICIs therapy was performed. Results: In all, 98 patients were included. Lower baseline 18F-FDG PET/CT parameters were associated with responses to ICIs. Patients with low wMTV or wTLG had improved PFS and OS. High wTLG, strong tumor expression of glucose transporter-1, and lack of responses were significantly associated. Patients with low glycolytic parameters benefited from ICIs, regardless of chemotherapy. Conversely, those with high parameters benefited from the addition of chemotherapy. Patients with higher wTLG and lower PD-L1 were associated with progression and worse survival to ICIs monotherapy. Conclusions: Glycolytic metabolic profiles established through baseline 18F-FDG PET/CT are useful biomarkers for evaluating ICI therapy in advanced NSCLC.

1 November 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
LFLeonardo Da Fonseca
Leonardo Da Fonseca
VYVictor Junji Yamamoto
Victor Junji Yamamoto
MCMateus Trinconi Cunha
Mateus Trinconi Cunha
GTGiovanna Sawaya Torre
Giovanna Sawaya Torre
RARaphael Lc Araujo
Raphael Lc Araujo
FCFlair Jose Carrilho
Flair Jose Carrilho
Purpose: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare primary liver malignancy often diagnosed at advanced stages. While there are limited data on the efficacy of specific agents, we aim to report outcomes of patients treated with systemic therapies and explore prognostic factors. Patients and Methods: Medical records of patients treated between 2010 and 2022 were reviewed. Treatments were defined after multidisciplinary assessment. Descriptive statistics were used for baseline demographics. Time-to-event outcomes were estimated using the Kaplan–Meier method, compared by log-rank and adjusted by a regression model. Radiomic features (including size, shape, and texture) of the primary lesion were extracted and dimensionality reduced. An unsupervised Gaussian Mixture Model (GMM) clustering was performed, and survival was compared between clusters. Results: We identified 23 patients: 12 males, with a median age of 23.6 years. At diagnosis, 82.6% had metastases, most frequently to the lungs (39.1%), lymph nodes (39.1%), and peritoneum (21.7%). Patients received a median of three lines (1– 8) of treatment, including different regimens. Sorafenib (39.1%), capecitabine (30.4%), and capecitabine/interferon (13%) were the most used first-line regimens. The median time-to-failure was 3.8 months (95% CI: 3.2– 8.7). Capecitabine + interferon (42.1%) and platinum combinations (39.1%) were the most used second-line regimens, with a time-to-failure of 3.5 months (95% CI: 1.5– 11.6). Median overall survival was 26.7 months (95% CI: 15.1– 40.4). A high baseline neutrophil-to-lymphocyte ratio (NLR) was associated with worse survival (p=0.02). Radiomic features identified three clusters, with one cluster (n=6) having better survival (40.4 vs 22.6 months, p=0.039). Tumor sphericity in the arterial phase was the most relevant characteristic associated with a better prognosis (accuracy=0.93). Conclusion: FLHCC has unique features compared to conventional HCC, including young onset, gender balance, and absence of hepatopathy. Systemic therapies can provide encouraging survival, but lack of uniformity precludes defining a preferable regimen. Radiomics and NLR were suggested to correlate with prognosis and warrant further validation.

30 May 2025 in Cancer
Verified
Journal Article
Open access
MCMateus Trinconi Cunha
Mateus Trinconi Cunha
NWNeil Wallace
Neil Wallace
SPSandro Porceddu
Sandro Porceddu
RFRenata Ferrarotto
Renata Ferrarotto
Antibodies against PD‐1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.

26 September 2022 in Cancer Medicine
Verified
Journal Article
Open access
MCMateus Trinconi Cunha
Mateus Trinconi Cunha
ABAna Paula de Souza Borges
Ana Paula de Souza Borges
VJVinicius Carvalho Jardim
Vinicius Carvalho Jardim
AFAndré Fujita
André Fujita
GCGilberto de Castro
Gilberto de Castro
Background: Patients with advanced non‐small cell lung cancer (NSCLC) are a heterogeneous population with short lifespan. We aimed to develop methods to better differentiate patients whose survival was >90 days.Methods: We evaluated 83 characteristics of 106 treatment‐naïve, stage IV NSCLC patients with Eastern Cooperative Oncology Group Performance Status (ECOG‐PS) >1. Automated machine learning was used to select a model and optimize hyperparameters. 100‐fold bootstrapping was performed for dimensionality reduction for a second (“lite”) model. Performance was measured by C‐statistic and accuracy metrics in an out‐of‐sample validation cohort. The “lite” model was validated on a second independent, prospective cohort (N = 42). Network analysis (NA) was performed to evaluate the differences in centrality and connectivity of features.Results: The selected method was ExtraTrees Classifier, with C‐statistic of 0.82 (p < 0.01) and accuracy of 0.81 (p = 0.01). The “lite” model had 16 variables and obtained C‐statistic of 0.84 (p < 0.01) and accuracy of 0.75 (p = 0.039) in the first cohort, and C‐statistic of 0.706 (p < 0.01) and accuracy of 0.714 (p < 0.01) in the second cohort. The networks of patients with lower survival were more interconnected. Features related to cachexia, inflammation, and quality of life had statistically different prestige scores in NA.Conclusions: Machine learning can assist in the prognostic evaluation of advanced NSCLC. The model generated with a reduced number of features showed high accessibility and reasonable metrics. Features related to quality of life, cachexia, and performance status had increased correlation and importance scores, suggesting that they play a role at later disease stages, in line with the biological rationale already described.

24 March 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
GPGabriel Berlingieri Polho
Gabriel Berlingieri Polho
MCMateus Trinconi Cunha
Mateus Trinconi Cunha
MCMaiana Hamdan Melo Coelho
Maiana Hamdan Melo Coelho
JAJamile Almeida-Silva
Jamile Almeida-Silva
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
JMJose Mauricio Mota
Jose Mauricio Mota